Clinical Research in Cardiology

, Volume 104, Issue 3, pp 241–249 | Cite as

Effects of β-blocker therapy on electrocardiographic and echocardiographic characteristics of left ventricular noncompaction

  • Jin Li
  • Jennifer Franke
  • Regina Pribe-Wolferts
  • Benjamin Meder
  • Philipp Ehlermann
  • Derliz Mereles
  • Florian Andre
  • Mohamed Assem Abdelrazek
  • Constanze Merten
  • Patrick A. Schweizer
  • Rüdiger Becker
  • Hugo A. Katus
  • Dierk ThomasEmail author
Original Paper


Left ventricular noncompaction (LVNC) is a cardiomyopathy with hypertrabeculation of the LV, often complicated by heart failure, arrhythmia and thromboembolic events. The features of LVNC are still incompletely characterized due to its late recognition as clinically relevant condition. The aims of this study were to describe echocardiographic and electrophysiologic characteristics of LVNC patients and to assess the effects of chronic β-blocker treatment. Study patients (n = 20; 42.5 [36.3; 52.5] years; 12 men) exhibited reduced LV ejection fraction (median LVEF = 32 %) and an increased LV mass of 210 g. Sinus rhythm was present in 19 patients, whereas one patient was in atrial fibrillation. Baseline heart rate was 77.5 beats per minute. Left bundle branch block was detected in five cases. In a subgroup of patients receiving β-blocker therapy (n = 17), LV mass was reduced from 226 [178; 306] g to 220 [169; 254] g (p = 0.007) at 13 ± 6 months follow-up. By contrast, a subgroup of three patients that were not treated with an anti-β-adrenergic agent showed LV mass increase from 180 [169; 197] g to 199 [185; 213] g (p = 0.023). LVEF and electrocardiographic parameters were not significantly modulated during chronic β-blocker treatment. There was no sustained symptomatic ventricular tachyarrhythmia, thromboembolic event or death in either group. In conclusion, this study reveals reduction of LV mass among LVNC patients during β-blocker therapy. Effects of β-blocker treatment in LVNC require validation in prospective controlled studies.


β-blocker Cardiomyopathy Hypertrabeculation Left ventricular noncompaction Remodeling 



This study was supported in part by research grants from the DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung—German Center for Cardiovascular Research) and from the BMBF (German Ministry of Education and Research) (to B.M., P.A.S., H.A.K. and D.T.).

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Oechslin E, Jenni R (2011) Left ventricular non-compaction revisited: a distinct phenotype with genetic heterogeneity? Eur Heart J 32:1446–1456. doi: 10.1093/eurheartj/ehq508 CrossRefPubMedGoogle Scholar
  2. 2.
    Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R (1990) Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 82:507–513. doi: 10.1161/01.CIR.82.2.507 CrossRefPubMedGoogle Scholar
  3. 3.
    Junga G, Kneifel S, Von Smekal A, Steinert H, Bauersfeld U (1999) Myocardial ischaemia in children with isolated ventricular non-compaction. Eur Heart J 20:910–916. doi: 10.1053/euhj.1998.1398 CrossRefPubMedGoogle Scholar
  4. 4.
    Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R (2000) Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol 36:493–500. doi: 10.1016/S0735-1097(00)00755-5 CrossRefPubMedGoogle Scholar
  5. 5.
    Anderson RH (2008) Ventricular non-compaction—a frequently ignored finding? Eur Heart J 29:10–11. doi: 10.1093/eurheartj/ehm536 CrossRefPubMedGoogle Scholar
  6. 6.
    Sen-Chowdhry S, McKenna WJ (2008) Left ventricular noncompaction and cardiomyopathy: cause, contributor, or epiphenomenon? Curr Opin Cardiol 23:171–175. doi: 10.1097/HCO.0b013e3282fdc939 CrossRefPubMedGoogle Scholar
  7. 7.
    Stollberger C, Finsterer J (2004) Left ventricular hypertrabeculation/noncompaction. J Am Soc Echocardiogr 17:91–100. doi: 10.1016/S0894-7317(03)00514-5 CrossRefPubMedGoogle Scholar
  8. 8.
    Luxán G, Casanova JC, Martínez-Poveda B, Prados B, D’Amato G, MacGrogan D, Gonzalez-Rajal A, Dobarro D, Torroja C, Martinez F, Izquierdo-García JL, Fernández-Friera L, Sabater-Molina M, Kong YY, Pizarro G, Ibañez B, Medrano C, García-Pavía P, Gimeno JR, Monserrat L, Jiménez-Borreguero LJ, de la Pompa JL (2013) Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nat Med 19:193–201. doi: 10.1038/nm.3046 CrossRefPubMedGoogle Scholar
  9. 9.
    Schweizer PA, Schröter J, Greiner S, Haas J, Yampolsky P, Mereles D, Buss SJ, Seyler C, Bruehl C, Draguhn A, Koenen M, Meder B, Katus HA, Thomas D (2014) The symptom complex of familial sinus node dysfunction and myocardial non-compaction is associated with mutations in the HCN4 channel. J Am Coll Cardiol 64:757–767. doi: 10.1016/j.jacc.2014.06.1155 CrossRefPubMedGoogle Scholar
  10. 10.
    Hunt SA, American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46:e1–e82. doi: 10.1016/j.jacc.2005.08.022 CrossRefPubMedGoogle Scholar
  11. 11.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, American College of Cardiology Foundation; American Heart Association (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53:e1–e90. doi: 10.1016/j.jacc.2008.11.013 CrossRefPubMedGoogle Scholar
  12. 12.
    McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847. doi: 10.1093/eurjhf/hfs105 CrossRefPubMedGoogle Scholar
  13. 13.
    Pantazis AA, Elliott PM (2009) Left ventricular noncompaction. Curr Opin Cardiol 24:209–213. doi: 10.1097/HCO.0b013e32832a11e7 CrossRefPubMedGoogle Scholar
  14. 14.
    Thavendiranathan P, Dahiya A, Phelan D, Desai MY, Tang WH (2013) Isolated left ventricular non-compaction controversies in diagnostic criteria, adverse outcomes and management. Heart 99:681–689. doi: 10.1136/heartjnl-2012-302816 CrossRefPubMedGoogle Scholar
  15. 15.
    Stollberger C, Finsterer J, Blazek G (2002) Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. Am J Cardiol 90:899–902. doi: 10.1016/S0002-9149(02)02723-6 CrossRefPubMedGoogle Scholar
  16. 16.
    Finsterer J, Stollberger C (2011) No rationale for a diagnostic ratio in left ventricular hypertrabeculation/noncompaction. Int J Cardiol 146:91–92. doi: 10.1016/j.ijcard.2010.02.043 CrossRefPubMedGoogle Scholar
  17. 17.
    Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463. doi: 10.1016/j.echo.2005.10.005 CrossRefPubMedGoogle Scholar
  18. 18.
    Chiladakis J, Kalogeropoulos A, Arvanitis P, Koutsogiannis N, Zagli F, Alexopoulos D (2010) Heart rate-dependence of QTc intervals assessed by different correction methods in patients with normal or prolonged repolarization. Pacing Clin Electrophysiol 33:553–560. doi: 10.1111/j.1540-8159.2009.02657.x CrossRefPubMedGoogle Scholar
  19. 19.
    Rautaharju PM, Zhang ZM, Prineas R, Heiss G (2004) Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol 93:1017–1021. doi: 10.1016/j.amjcard.2003.12.055 CrossRefPubMedGoogle Scholar
  20. 20.
    Ehlert FA, Goldberger JJ, Rosenthal JE, Kadish AH (1992) Relation between QT and RR intervals during exercise testing in atrial fibrillation. Am J Cardiol 70:332–338CrossRefPubMedGoogle Scholar
  21. 21.
    Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY, Vidal V, Bartoli JM, Habib G, Moulin G (2010) Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J 31:1098–1104. doi: 10.1093/eurheartj/ehp595 CrossRefPubMedGoogle Scholar
  22. 22.
    Steffel J, Kobza R, Oechslin E, Jenni R, Duru F (2009) Electrocardiographic characteristics at initial diagnosis in patients with isolated left ventricular noncompaction. Am J Cardiol 104:984–989. doi: 10.1016/j.amjcard.2009.05.042 CrossRefPubMedGoogle Scholar
  23. 23.
    Steffel J, Kobza R, Namdar M, Wolber T, Brunckhorst C, Lüscher TF, Jenni R, Duru F (2009) Electrophysiological findings in patients with isolated left ventricular non-compaction. Europace 11:1193–1200. doi: 10.1093/europace/eup187 CrossRefPubMedGoogle Scholar
  24. 24.
    Kobza R, Steffel J, Erne P, Schoenenberger AW, Hürlimann D, Lüscher TF, Jenni R, Duru F (2010) Implantable cardioverter-defibrillator and cardiac resynchronization therapy in patients with left ventricular noncompaction. Heart Rhythm 7:1545–1549. doi: 10.1016/j.hrthm.2010.05.025 CrossRefPubMedGoogle Scholar
  25. 25.
    Greutmann M, Mah ML, Silversides CK, Klaassen S, Attenhofer Jost CH, Jenni R, Oechslin EN (2012) Predictors of adverse outcome in adolescents and adults with isolated left ventricular noncompaction. Am J Cardiol 109:276–281. doi: 10.1016/j.amjcard.2011.08.043 CrossRefPubMedGoogle Scholar
  26. 26.
    Steffel J, Duru F (2012) Rhythm disorders in isolated left ventricular noncompaction. Ann Med 44:101–108. doi: 10.3109/07853890.2011.554427 CrossRefPubMedGoogle Scholar
  27. 27.
    Amann U, Kirchberger I, Heier M, Golüke H, von Scheidt W, Kuch B, Peters A, Meisinger C (2014) Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA myocardial infarction registry. Clin Res Cardiol 103:655–664. doi: 10.1007/s00392-014-0688-0 PubMedGoogle Scholar
  28. 28.
    Lonn EM, Rambihar S, Gao P, Custodis FF, Sliwa K, Teo KK, Yusuf S, Böhm M (2014) Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol 103:149–159. doi: 10.1007/s00392-013-0644-4 CrossRefPubMedGoogle Scholar
  29. 29.
    Liosis S, Bauer T, Schiele R, Gohlke H, Gottwik M, Katus H, Sabin G, Zahn R, Schneider S, Rauch B, Senges J, Zeymer U (2013) Predictors of 1 year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study. Clin Res Cardiol 102:671–677. doi: 10.1007/s00392-013-0581-2 CrossRefPubMedGoogle Scholar
  30. 30.
    Franke J, Wolter JS, Meme L, Keppler J, Tschierschke R, Katus HA, Zugck C (2013) Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol 102:23–31. doi: 10.1007/s00392-012-0489-2 CrossRefPubMedGoogle Scholar
  31. 31.
    Werdan K, Ebelt H, Nuding S, Höpfner F, Hack G, Müller-Werdan U (2012) Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol 101:365–373. doi: 10.1007/s00392-011-0402-4 CrossRefPubMedGoogle Scholar
  32. 32.
    Fujita B, Franz M, Goebel B, Fritzenwanger M, Figulla HR, Kuethe F, Ferrari M, Jung C (2012) Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy. Clin Res Cardiol 101:701–707. doi: 10.1007/s00392-012-0447-z CrossRefPubMedGoogle Scholar
  33. 33.
    Franke J, Zugck C, Wolter JS, Frankenstein L, Hochadel M, Ehlermann P, Winkler R, Nelles M, Zahn R, Katus HA, Senges J (2012) A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clin Res Cardiol 101:1–10. doi: 10.1007/s00392-011-0348-6 CrossRefPubMedGoogle Scholar
  34. 34.
    Remme WJ (2010) Which beta-blocker is most effective in heart failure? Cardiovasc Drugs Ther 24:351–358. doi: 10.1007/s10557-010-6247-7 CrossRefPubMedGoogle Scholar
  35. 35.
    Rehsia NS, Dhalla NS (2010) Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol 15:e86–e95PubMedCentralPubMedGoogle Scholar
  36. 36.
    Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35:569–582. doi: 10.1016/S0735-1097(99)00630-0 CrossRefPubMedGoogle Scholar
  37. 37.
    Waagstein F (2002) Beta-blockers in congestive heart failure: the evolution of a new treatment concept—mechanisms of action and clinical implications. J Clin Basic Cardiol 3:215–223Google Scholar
  38. 38.
    van de Ven LL, van Veldhuisen DJ, Goulder M, Zilahi Z, Meyer WR, Willenheimer R (2010) The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. Int J Cardiol 144:59–63. doi: 10.1016/j.ijcard.2009.04.040 CrossRefPubMedGoogle Scholar
  39. 39.
    Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7–13. doi: 10.1016/S0140-6736(03)13800-7 CrossRefPubMedGoogle Scholar
  40. 40.
    Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ (1995) Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25:1154–1161. doi: 10.1016/0735-1097(94)00543-Y CrossRefPubMedGoogle Scholar
  41. 41.
    Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C (2004) Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 25:1341–1362. doi: 10.1016/j.ehj.2004.06.002 CrossRefPubMedGoogle Scholar
  42. 42.
    Toyono M, Kondo C, Nakajima Y, Nakazawa M, Momma K, Kusakabe K (2001) Effects of carvedilol on left ventricular function, mass, and scintigraphic findings in isolated left ventricular non-compaction. Heart 86:E4. doi: 10.1136/heart.86.1.e4 CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Jin Li
    • 1
  • Jennifer Franke
    • 1
  • Regina Pribe-Wolferts
    • 1
  • Benjamin Meder
    • 1
  • Philipp Ehlermann
    • 1
  • Derliz Mereles
    • 1
  • Florian Andre
    • 1
  • Mohamed Assem Abdelrazek
    • 1
    • 2
  • Constanze Merten
    • 1
    • 3
  • Patrick A. Schweizer
    • 1
  • Rüdiger Becker
    • 1
    • 4
  • Hugo A. Katus
    • 1
  • Dierk Thomas
    • 1
    Email author
  1. 1.Department of CardiologyUniversity Hospital of HeidelbergHeidelbergGermany
  2. 2.Radiology DepartmentCairo University HospitalCairoEgypt
  3. 3.Heart CenterSegeberger Kliniken GmbHBad SegebergGermany
  4. 4.Department of Cardiology, Angiology, Nephrology and Intensive CareKlinikum WolfsburgWolfsburgGermany

Personalised recommendations